<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939055</url>
  </required_header>
  <id_info>
    <org_study_id>D00764</org_study_id>
    <nct_id>NCT00939055</nct_id>
  </id_info>
  <brief_title>StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight</brief_title>
  <official_title>A Randomized Controlled Trial of StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoGastric Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EndoGastric Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Roux-en-Y gastric bypass (RNYGB) is a weight loss surgery that involves the creation of a&#xD;
      small gastric pouch and rearrangement of the small intestine. Although RNYGB has been&#xD;
      demonstrated as an effective bariatric procedure, a significant number of patients experience&#xD;
      weight regain that is often associated with distended gastric anatomy. Open and laparoscopic&#xD;
      approaches for revision are associated with higher complication rates than de novo&#xD;
      procedures. This study will evaluate the safety and effectiveness of a revisional&#xD;
      incisionless natural orifice surgery of the gastric pouch and stoma in producing weight loss&#xD;
      in post-RNYGB patients who have experienced weight regain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Roux-en-Y gastric bypass (RNYGB) is the most commonly performed bariatric procedure to&#xD;
      treat morbid obesity 1. Numerous studies have documented the effectiveness of RNYGB in&#xD;
      promoting excess weight loss (EWL) typically in the 65-80% range after 1.5 to 2 years 1.&#xD;
      Despite the favorable short-term outcomes of this bariatric surgical procedure, approximately&#xD;
      10-40% of patients do not achieve successful long-term weight loss 2. The weight regain&#xD;
      occurs typically within 2 to 7 years after RNYGB surgery and is associated primarily with&#xD;
      dilation of the gastric pouch or stoma 3, 4. Several open and laparoscopic bariatric revision&#xD;
      procedures have been used in an attempt to correct these dilations, but they all have been&#xD;
      associated with serious complications such as perforations, obstruction, staple line&#xD;
      disruption, blind loop syndrome, stoma ulcer, and incisional hernias 2, 5, 6. Because of this&#xD;
      high rate of morbidity associated with revisional gastric bypass surgery, less invasive&#xD;
      endoscopic procedures may become a preferred approach for weight regain after RNYGB 7, 8.&#xD;
&#xD;
      The StomaphyX delivery system with SerosaFuse fasteners consist of an ergonomic, flexible&#xD;
      fastener delivery device and sterile polypropylene fastener implants. The unit is provided&#xD;
      sterile and is a single use device. The polypropylene fasteners are proprietary and function&#xD;
      only with the StomaphyX device. The device uses vacuum to invaginate tissue through a port&#xD;
      into a chamber and fasten it using the H shaped polypropylene fasteners. The fastener&#xD;
      delivery subsystem is comprised of 3 elements: stylet, pusher, and internal lumens. They run&#xD;
      the length of the device, the pusher being a hollow tube that rides over the length of the&#xD;
      stylet, both riding in the lumen. The stylet is sharp at the distal tip to pierce tissue. The&#xD;
      fastener is loaded by snapping it onto the stylet in the loading port of the handle. When&#xD;
      pushed by the operator, the stylet carries the fastener down the lumen which runs from the&#xD;
      proximal handle assembly to the distal tissue port where it will eventually be deployed into&#xD;
      the tissue. Durability of the SerosaFuse fasteners has been demonstrated during several&#xD;
      clinical studies utilizing the EsophyX device 9-12.&#xD;
&#xD;
      Reason for Conducting the Present Study: The goal of this study was to investigate the safety&#xD;
      and effectiveness of the StomaphyX device for revisional natural orifice surgery of the&#xD;
      gastric pouch and gastrojejunostomy anastomosis (stoma) in RNYGB patients to reduce regained&#xD;
      weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on futility analysis, study would not meet primary endpoint.&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>12 month</time_frame>
    <description>A clinically significant reduction in pre-RNYGB excess weight, defined by ≥15% EBL and BMI &lt; 35.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Changes to Quality of Life (QOL) Using a Validated QOL Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life as assessed by the Impact of Weight on Quality of Life Questionnaire (IWQOL-Lite); a ≥ 10 total score improvement from baseline (screening) will represent a clinically significant improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>StomaphyX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-Roux-en-Y revisional surgery using the StomaphyX device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>StomaphyX</intervention_name>
    <description>Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.</description>
    <arm_group_label>StomaphyX</arm_group_label>
    <other_name>transoral incisionless fastening device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>False procedure</description>
    <arm_group_label>Sham Procedure</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age and less than 65 years of age&#xD;
&#xD;
          -  BMI of at least 35 and no more than 40&#xD;
&#xD;
          -  At least 2 years post-RNYGB surgery&#xD;
&#xD;
          -  Initially achieved at least 60% EBL and a BMI 35 or less&#xD;
&#xD;
          -  Regained at least 20% of pre-RNYGB excess weight at screening&#xD;
&#xD;
          -  Stable weight or continued failure to lose weight for at least 3 months&#xD;
&#xD;
          -  Enlarged gastric pouch (≥ 30 ml)&#xD;
&#xD;
          -  Anatomy of upper GI judged suitable for revision using StomaphyX&#xD;
&#xD;
          -  Completed successful nutritional screening&#xD;
&#xD;
          -  Normal levels of vitamin D, iron/ferritin, calcium, and magnesium&#xD;
&#xD;
          -  Absence of protein malnutrition confirmed by serum albumin &gt; 3 g/dL&#xD;
&#xD;
          -  Willing to cooperate with follow-up dietary recommendations and assessment tests&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous revisional bariatric surgery after RNYGB&#xD;
&#xD;
          -  Esophageal stricture or any anatomic condition that precludes passage of the StomaphyX&#xD;
             device to the gastric pouch&#xD;
&#xD;
          -  Diabetes type I&#xD;
&#xD;
          -  Causal factors for weight regain other than gastric pouch enlargement&#xD;
&#xD;
          -  Serious complications experienced during and/or after RNYGB such as leaks, fistula,&#xD;
             incisional hernia, ulcers, pulmonary embolism or deep venous thrombosis&#xD;
&#xD;
          -  Pregnancy or plans of pregnancy in the next 12 months&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  ASA &gt; 3&#xD;
&#xD;
          -  Life expectancy less than one year&#xD;
&#xD;
          -  An eating disorder, as defined by the Diagnostic and Statistical Manual of Mental&#xD;
             Disorders, 4th Ed, Washington DC, American Psychiatric Association, 2000&#xD;
&#xD;
          -  Active substance abuse&#xD;
&#xD;
          -  Plans of smoking cessation in the next 12 months&#xD;
&#xD;
          -  Treatment with weight-loss prescription drug therapy within three months preceding the&#xD;
             screening&#xD;
&#xD;
          -  Intention to use prescription drug therapy or the use of over-the-counter weight-loss&#xD;
             preparations during the current study&#xD;
&#xD;
          -  Current participant in another weight-loss study or other clinical trial&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Presence of ulceration at the gastrojejunostomy anastomosis&#xD;
&#xD;
          -  Portal hypertension&#xD;
&#xD;
          -  Coagulation disorders or chronic use of anticoagulants&#xD;
&#xD;
          -  Any active medical condition that would preclude the patient from completing the study&#xD;
             or would result in an unreasonable risk to the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita P. Courcoulas, MD MPH FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <results_first_submitted>March 24, 2014</results_first_submitted>
  <results_first_submitted_qc>May 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>StomaphyX</title>
          <description>Post-Roux-en-Y revisional surgery using the StomaphyX device.&#xD;
StomaphyX: Revisional incisionless natural orifice surgery of gastric pouch and stoma.&#xD;
GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications</description>
        </group>
        <group group_id="P2">
          <title>Sham Procedure</title>
          <description>No intervention&#xD;
Sham procedure: False procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinuation prior to procedure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 112 patients entered the study. 73 patients were randomized to the treatment study arm while 39 patients were randomized to the control study arm. 4 patients discontinued participation prior to receiving the study procedure. Therefore, 108 patients were eligible for follow-up.</population>
      <group_list>
        <group group_id="B1">
          <title>StomaphyX</title>
          <description>Post-Roux-en-Y revisional surgery using the StomaphyX device.&#xD;
StomaphyX: Revisional incisionless natural orifice surgery of gastric pouch and stoma.&#xD;
GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications</description>
        </group>
        <group group_id="B2">
          <title>Sham Procedure</title>
          <description>No intervention&#xD;
Sham procedure: False procedure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="8.62"/>
                    <measurement group_id="B2" value="49" spread="7.35"/>
                    <measurement group_id="B3" value="49" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight Loss</title>
        <description>A clinically significant reduction in pre-RNYGB excess weight, defined by ≥15% EBL and BMI &lt; 35.</description>
        <time_frame>12 month</time_frame>
        <population>When futility analysis was performed, only 46 out of 108 patients had reached the 12 month primary endpoint. Analysis was performed on the 29 StomaphyX-treated patients to determine whether study objectives were met. Sham (control) patients were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>StomaphyX</title>
            <description>Post-Roux-en-Y revisional surgery using the StomaphyX device.&#xD;
StomaphyX: Revisional incisionless natural orifice surgery of gastric pouch and stoma.&#xD;
GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>No intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss</title>
          <description>A clinically significant reduction in pre-RNYGB excess weight, defined by ≥15% EBL and BMI &lt; 35.</description>
          <population>When futility analysis was performed, only 46 out of 108 patients had reached the 12 month primary endpoint. Analysis was performed on the 29 StomaphyX-treated patients to determine whether study objectives were met. Sham (control) patients were not analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Changes to Quality of Life (QOL) Using a Validated QOL Questionnaire</title>
        <description>Quality of life as assessed by the Impact of Weight on Quality of Life Questionnaire (IWQOL-Lite); a ≥ 10 total score improvement from baseline (screening) will represent a clinically significant improvement.</description>
        <time_frame>12 months</time_frame>
        <population>Secondary endpoint was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>StomaphyX</title>
            <description>Post-Roux-en-Y revisional surgery using the StomaphyX device.&#xD;
StomaphyX: Revisional incisionless natural orifice surgery of gastric pouch and stoma.&#xD;
GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>No intervention&#xD;
Sham procedure: False procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Changes to Quality of Life (QOL) Using a Validated QOL Questionnaire</title>
          <description>Quality of life as assessed by the Impact of Weight on Quality of Life Questionnaire (IWQOL-Lite); a ≥ 10 total score improvement from baseline (screening) will represent a clinically significant improvement.</description>
          <population>Secondary endpoint was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected through the 12-month post-op visit for treatment and sham patients. The blind was broken for all patients due to premature termination of the study.</time_frame>
      <desc>112 subjects enrolled/randomized:73 StomaphyX, 39 Sham. 108 treated:69 StomaphyX, 39 Sham. 112 patients were considered at risk for all cause mortality; 108 (69 StomaphyX, 39 Sham) considered at risk for serious/other adverse events. The 4 patients not included were in StomaphyX arm: 2 withdrawn prior to treatment at investigator discretion. Surgery was aborted on the other 2; treatment not completed as device couldn't be inserted. These 4 followed per site standard of care, outside study.</desc>
      <group_list>
        <group group_id="E1">
          <title>StomaphyX</title>
          <description>Post-Roux-en-Y revisional surgery using the StomaphyX device.&#xD;
StomaphyX: Revisional incisionless natural orifice surgery of gastric pouch and stoma.&#xD;
GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>No intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tachycardia, Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Perforation</sub_title>
                <description>Small perforation in posterior gastrojejunostomy anastomosis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sore Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Temporary epigastric or abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>can be treated with standard pain medication</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain (e.g. throat pain)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Burps a lot after eating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Temporary dysphagia (i.e. difficulty swallowing)</sub_title>
                <description>due to swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Affairs</name_or_title>
      <organization>EndoGastric Solutions</organization>
      <phone>650-823-9093</phone>
      <email>gsahyun@endogastricsolutions.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

